Valirx (VAL) RNS Announcements

Add to Alert list
Date Time Source Announcement
03 Oct 2013 07:00 AM
RNS
Re: VAL201 - Filing of Phase IB Clinical Trial
05 Sep 2013 07:00 AM
RNS
Half Yearly Report
15 Aug 2013 07:00 AM
RNS
Consortium incl. ValiRx Awarded Eurostars Grant
31 Jul 2013 07:00 AM
RNS
Update
25 Jun 2013 07:00 AM
RNS
Investor Presentation in Manchester
13 Jun 2013 07:00 AM
RNS
Re: VAL201 Update
06 Jun 2013 10:00 AM
RNS
ValiRx admitted as founder member of the SSE
25 Apr 2013 07:00 AM
RNS
New Patent Granted
22 Apr 2013 11:52 AM
RNS
Result of AGM
02 Apr 2013 07:00 AM
RNS
Update on Developmental and Clinical Activity
28 Mar 2013 07:01 AM
RNS
Final Results
21 Feb 2013 07:00 AM
RNS
Re Commercial Development Update
23 Jan 2013 07:00 AM
RNS
Appointment of Medical Monitoring Officer
31 Dec 2012 07:00 AM
RNS
Total Voting Rights
22 Nov 2012 07:00 AM
RNS
Re: Update
19 Nov 2012 12:19 PM
RNS
Result of General Meeting
01 Nov 2012 01:49 PM
RNS
Placing and Notice of General Meeting
11 Oct 2012 07:00 AM
RNS
re: UK Distribution Agreement
20 Sep 2012 07:00 AM
RNS
Half Yearly Report
06 Sep 2012 07:00 AM
RNS
VAL201 Update re: Breast Cancer Study
02 Aug 2012 07:00 AM
RNS
Re: GeneICE and Biomarkers Development Update
29 May 2012 11:07 AM
RNS
Result of AGM
29 May 2012 07:00 AM
RNS
Update re: Late Pre-clinical Study of VAL201
15 May 2012 07:00 AM
RNS
New US Patent Grant
27 Apr 2012 07:00 AM
RNS
Final Results
02 Apr 2012 12:17 PM
RNS
Director/PDMR Shareholding
02 Apr 2012 07:00 AM
RNS
Placing of GBP 900,000 and Director's Dealing
29 Mar 2012 07:00 AM
RNS
Re Agreement
08 Mar 2012 07:00 AM
RNS
Peer Review Findings Published re VAL201
14 Feb 2012 07:00 AM
RNS
Establishment of Scientific & Advisory Board
02 Feb 2012 07:00 AM
RNS
New European Patent Grant
31 Jan 2012 10:14 AM
RNS
Total Voting Rights
05 Jan 2012 07:00 AM
RNS
Acquisition
15 Dec 2011 07:00 AM
RNS
New Patent Grant for GeneICE & VAL101 Update
09 Dec 2011 04:23 PM
RNS
Re Volition - Allotment of Shares
24 Nov 2011 07:00 AM
RNS
Appointment of SELFCheck Distributor
24 Nov 2011 07:00 AM
RNS
Holding(s) in Company
03 Nov 2011 07:00 AM
RNS
New Patent Filing
07 Oct 2011 08:00 AM
RNS
Volition Update
29 Sep 2011 07:00 AM
RNS
Re BioPartnering Europe 2011 Conference
27 Sep 2011 07:00 AM
RNS
Volition Update
22 Sep 2011 07:00 AM
RNS
Half Yearly Report
13 Sep 2011 07:00 AM
RNS
Re: Collaborative Agreement
08 Sep 2011 07:00 AM
RNS
Distribution Agreement
18 Aug 2011 07:00 AM
RNS
Acquisition of Finnish Non-Trading Company
28 Jul 2011 07:00 AM
RNS
VAL201 Update
19 Jul 2011 03:59 PM
RNS
Holding(s) in Company
14 Jul 2011 07:00 AM
RNS
Director/PDMR Shareholding
11 Jul 2011 07:00 AM
RNS
Grant of Options
23 Jun 2011 10:55 AM
RNS
Result of AGM

ValiRx PLC: A Biotech Innovator on the London Stock Exchange (LSE)

ValiRx PLC, known by its ticker symbol VAL, is a trailblazer in the biotechnology sector. Its performance on the London Stock Exchange (LSE) has been remarkable, with the ValiRx share price reflecting the company's consistent growth and success.

As a member of the LSE, ValiRx PLC aligns with the London Stock Exchange Group's (LSEG) mission of supporting innovative and growing businesses. The LSEG recognises ValiRx PLC as a significant player, contributing to the robust and diverse ecosystem of the LSE.

The ValiRx share price on the LSE not only underscores its financial stability but also its strategic vision in the biotechnology industry. ValiRx PLC's journey on the LSE is a testament to its robust business model and its ability to create value for its stakeholders.

In conclusion, ValiRx PLC's association with the LSE and LSEG symbolises its commitment to growth, innovation, and value creation. As ValiRx PLC continues to thrive on the LSE, it sets the bar high for the biotechnology industry, contributing to the dynamic and diverse ecosystem of the LSEG. With its focus on cancer therapeutics, ValiRx is a key player in the healthcare sector, making strides in medical research and development.

UK 100

Latest directors dealings